The treatment of patients with advanced breast cancer using combination chemotherapy can cause significant toxicity without greatly prolonging survival (Powles et al., 1980; A'Hern et al., 1988) . Recently, studies have been reported in which low-toxicity regimens (single agent or short term) have achieved palliation without affecting survival (Chlebowski et al., 1989; Harris et al., 1990) . For example, Jones has reported a response rate of 43% with epirubicin given with a weekly dose of approximately 20 mg. No significant myelosuppression, and minimal nausea and alopecia resulted (Jones, 1988) . Further studies have shown no improvement in response rates by doubling the weekly dose from 20 to 40 mg. There was, however, a considerable increase in toxicity (Ebbs et al., 1989) .
There is a danger that such low toxicity regimens may be accepted without adequate comparison with conventional combination cytotoxics. One of the most widely used regimens in advanced breast cancer is the standard Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) treatment which achieves response rates of up to 60% (Bonadonna & Van Oosterom, 1983) . This was therefore chosen as the control arm of a direct comparison with low-dose weekly epirubicin. As reduced toxicity was central to the development of the low-dose regimen, the trial was planned around detailed measurement of Quality of Life. Between October 1988 and December 1989, 40 Table I ).
Patients and methods

Patients
Ethical considerations
The trial was approved by the ethical committees in both participating hospitals. Written informed consent was obtained from the patients prior to randomisation.
Treatment
All therapy was given in the outpatient clinic by one person. The dose schedules were: (1) Epirubicin 20 mg intravenously, given into fast-running 0.9% saline every 7 days; (2) Cyclo- (Hunt et al., 1985) and Linear Analogue Self Assessment (Priestman & Baum, 1976) at the start of treatment and four weekly thereafter; throughout treatment, patients completed the Qualitator daily diary card, a new instrument developed for breast cancer chemotherapy trials (Fraser et al., 1990) . Full blood count was measured prior to administration of intravenous cytotoxics. Patient characteristics were compared using the Chi-squared and t-tests.
Survival and. response analysis UICC criteria of response were assessed 4 weekly. The WHO toxicity criteria were recorded every 4 weeks. UICC response rates were compared using the Chi-squared test and time to treatment failure and survival analyses were done using the Kaplan-Meier life table method (Kaplan & Meier, 1958) and log rank test (Peto et al., 1977) . Correlation between initial QoL scores and survival were done using Spearman's rank correlation method. (X2=4.30, 1 d.f., P<0.05) .
The time to treatment failure was longer for CMF patients than epirubicin patients: median 24 weeks and 7 weeks (X2 = 5.17, 1 d.f., P < 0.05, see Figure 1 ).
Survival
Survival was similar in both treatment groups: medians 57 weeks and 55 weeks respectively (X2 = 1.38; 1 d.f., P= 0.24) (see Figure 2) . UICC responders, as expected from many previous studies (A 'Hern et al., 1988) survived longer than that non-responders: medians 87 weeks and 30 weeks (x2= 5.42, 1 d.f., P<0.05, see Figure 3 ). Figure  4 , in which the LASA, NHP and Qualitator scores are standardised to a scale of 0-10. Patients' QoL scores at the start of the study were correlated by rank with their subsequent survival. The Spearman co-efficients were -0.52 (95% c.i., -0.72, -0.23) for the LASA, -0.35 (-0.60, 0.04) for the NHP, -0.64 (-0.82, -0.36) for the Qualitator.
Quality of life during treatment
Compliance for the 29 patients who started the Qualitator, the 37 who started the NHP and 36 who started the LASA respectively were 88%, 89% and 92%. Figure 5 shows the mean global QoL values in each treatment group at each stage for all patients remaining in the study. The means are used purely for graphic representation: statistical comparison between treatment groups was by a rank test at each 4 weeks.
By 3 months, the scores of patients with a UICC response in both the epirubicin and CMF treatment groups had improved significantly in the Qualitator (medians 60.5 to 48, pretreatment difference in scores between responders and non-responders persisted on each monthly comparison: one month (LASA P <0.02, NHP P <0.01, Qualitator P <0.05), 2 months (Qualitator P<0.05), 3 months (NHP P<0.05, Qualitator P<0.01) and 4 months (NHP P<0.05).
All of the QoL measures allow sub-analysis in considerable detail. In separate analysis of the six domains of the NHP (emotional state, energy, pain, physical mobility, sleep and social factors) and the LASA and Qualitator symptoms in four sub-groups (physical symptoms, social factors, emotional factors and physical performance), non-responders had worse scores at most stages (see accompanying paper in this issue). The only significant difference between treatment groups was a better score in CMF than Epirubicin patients in the NHP score for pain at 2 months (median differences 0 and 9.5, P<0.05), energy at 3 months (medians 0 and 24, P < 0.05) and a worse Qualitator score at 3 months for personal relationships in CMF patients (median 7 and 7.65, P<0.05). In each case the high scores were amongst the non-responders in each group.
Discussion
One of the most difficult decisions facing clinicians treating patients with advanced breast cancer is what to do when second line hormone therapy fails. At what point does one advise chemotherapy, to whom and how aggressively? Until recent years, the success of a treatment regimen has been defined almost solely by tumour shrinkage. Although toxic side effects have been measured, there was little evidence of correlation with the patient's experience. The failure of many studies to show a survival advantage to any regimen caused some clinicians to question the merits of giving chemotherapy at all (Powles et al., 1980) . During the last decades, the concept of Quality of Life has become increasingly important in those patients in whom little survival advantage is anticipated through treatment and efforts were made to define and measure it (Fallowfield, 1990) . Increasing numbers, but still a minority, of studies measure QoL (Bryne, 1992) . The disparate instruments and periods of measurement have made it difficult to interpret how chemotherapy affects QoL for patients with advanced breast cancer. The aim of this study was to compare a standard combination regimen with a single agent regimen in which different toxicity and possibly different response rates could be anticipated, and whether a difference in survival or QoL would result. Detailed intermittent QoL measurement was made with three instruments, two of which were specifically designed for the task. The response data were consistent with previous studies in that the patients who had a measurable response enjoyed longer overall survival. Although survival among patients with non-progressive disease was better for CMF patients, the poor survival of CMF non-responders was enough to redress this balance so before treatment and at 3 months for the Nottingham Health Profile (17 patients) and Linear Analogue Self-Assessment (17 patients).
-r --T----T----i that survival for the two treatment groups as a whole was equal. Few studies are large enough to show a survival difference between treatment groups, but A'Hern et al. showed that a better response rate equated with longer median survival in a statistical overview of 50 chemotherapy trials . The QoL data were not wholly expected. Although Ebbs et al. (1988) had reported that good pre-treatment QoL scores were associated with a subsequent response, we found that there was a close correlation with subsequent duration of survival too. Morris and Sherwood (1987) described this in terminally ill patients, and Addington-Hall et al. (1990) used the Spitzer QoL Index (Spitzer et al., 1981) to predict duration of survival in 230 terminally ill patients. However, it was a surprise that even in this small study, such a consistent trend would emerge. In the context of patients with advanced breast cancer, this may be of significance in deciding on treatment. Low objective toxicity in patients treated with epirubicin was reflected in the recording of specific treatment-related symptoms in the Qualitator, but QoL scores overall were unaffected and resembled closely the global scores of the other two instruments.
Is a harsher regimen therefore the treatment of choice for advanced breast cancer? The evidence is that it does not impair QoL in non-responders of whom there are fewer anyway and QoL improves for responders, as previously reported by Baum et al. (1980) . Coates et al. (1987) found that Quality of Life declined significantly in patients on a less aggressive regimen in which response was poorer and Slevin et al. (1990) found cancer patients much more willing to comtemplate radical chemotherapy than were their doctors for them. However, if pre-treatment QoL scores give not only a guide to response, but to survival as well, then perhaps those patients with clinically advanced disease in whom QoL is poor, who will not respond and whose survival will be poor should not be given chemotherapy at all. A different interpretation might be that those patients whose disease is not yet advanced enough to affect their QoL are those most likely to respond to treatment. In a recent study, patients with metastatic cancer of bowel, lung, pancreas or melanoma, who received conventional therapy, including chemotherapy, had no better survival than matched controls having 'alternative' therapy. Chemotherapy was not associated with a worse QoL, and although the change in QoL was similar in both groups, the patients treated conventionally started and finished with better QoL measurement. This may have been influenced by the social composition of the groups: a higher number of alternative therapy patients had degrees and poor QoL may have contributed to their decision to seek unproven therapy. The ideal study in such patients would be randomised, with an arm involving palliative care only (Cassileth et al., 1991) .
One way of resolving the difficulty would be to involve the patient more fully in the decision-making process. This approach was recently advocated in early breast cancer treatment by Wennberg and colleagues who have used interactive videotapes (Wall Street Journal, 1992) .
The present study does not provide solutions to these uncertainties. However, detailed QoL measurement is shown to add valuable and perhaps not wholly expected information in evaluating advanced breast cancer chemotherapy. QoL measurement may be of use in defining individual strategies. Only by including QoL measurement in more protocols will knowledge of its precise role become clear.
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